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Alexa Pohl1*, Sarah Cassidy1,2, Bonnie Auyeung1,3 and Simon Baron-Cohen1,4Abstract
Background: Prenatal exposure to increased androgens has been implicated in both polycystic ovary syndrome
(PCOS) and autism spectrum conditions (ASC), suggesting that PCOS may be increased among women with ASC.
One study suggested elevated steroidopathic symptoms (‘steroidopathy’) in women with ASC. As the symptoms are
not independent, we conducted a latent class analysis (LCA). The objectives of the current study are: (1) to test if
these findings replicate in a larger sample; and (2) to use LCA to uncover affected clusters of women with ASC.
Methods: We tested two groups of women, screened using the Autism Spectrum Quotient - Group 1: n = 415
women with ASC (mean age 36.39 ± 11.98 years); and Group 2: n = 415 controls (mean age 39.96 ± 11.92 years). All
participants completed the Testosterone-related Medical Questionnaire online. A multiple-group LCA was used to
identify differences in latent class structure between women with ASC and controls.
Results: There were significant differences in frequency of steroid-related conditions and symptoms between
women with ASC and controls. A two-class semi-constrained model best fit the data. Based on response patterns,
we identified the classes as ‘Typical’ and ‘Steroidopathic’. The prevalence of the ‘Steroidopathic’ class was significantly
increased within the ASC group (ΔG2 = 15, df =1, P = 0.0001). In particular, we confirmed higher frequencies of epilepsy,
amenorrhea, dysmenorrhea, severe acne, gender dysphoria, and transsexualism, and differences in sexual preference in
women with ASC.
Conclusions: Women with ASC are at increased risk for symptoms and conditions linked to steroids. LCA revealed this
steroidopathy despite the apparent underdiagnosis of PCOS.
Keywords: Autism, Sex steroids, Polycystic ovary syndrome, Testosterone, HormonesBackground
Atypical levels of sex steroid hormones and their biosyn-
thetic pathway have been associated with autism spectrum
conditions (ASC) or associated with autistic traits in genetic
[1-3], gene expression [4,5], serum [6,7], amniotic fluid [8]
and 2D:4D ratio of 2nd digit to 4th digit [9] studies. Ele-
vated levels of prenatal androgens such as fetal testosterone
(FT) during a critical period are hypothesized to contribute
to the etiology of ASC [10] as FT shapes neurological devel-
opment [11-13]. Prenatal androgens also contribute to the
programming of the hypothalamic-pituitary-gonadal (HPG)
axis [14,15], and elevated levels of prenatal androgens also
contribute to the etiology of polycystic ovary syndrome* Correspondence: ap728@medschl.cam.ac.uk
1Autism Research Centre, Department of Psychiatry, University of Cambridge,
Douglas House, 18B Trumpington Road, Cambridge CB2 8AH, UK
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reproduction in any medium, provided the or(PCOS) [16]. The present study further explores the link
between ASC and PCOS.
Many candidate genes implicated in ASC are also impli-
cated in female reproductive disorders. For example, a
shorter CAG variable number tandem repeat associated
with hypersensitivity of the androgen receptor [17] has
been linked to ASC [3], precocious puberty, and PCOS
[18]. CYP19A1, whose product aromatase converts testos-
terone to estradiol and androstenedione to estrone, has
been related to ASC [1], PCOS [19,20], and female hyper-
androgenism [21]. Additionally, CYP19A1 has been identi-
fied as a target of transcriptional regulators such as RORA,
which is associated with autism [2], autoimmunity [22]
and early age at menarche [23]. Another gene of interest
in both autism [1] and female reproductive disorders [24]
is CYP17A1, whose product 17α-hydroxylase/17,20 lysase/
17,20-desmolase catalyzes several steroidogenic reactions.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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PCOS [25], and its overexpression is driven by increased
insulin receptor signaling, [26] such that hyperinsulinemia
can eventually cause hyperandrogenemia [27]. Autism is as-
sociated with CYP11B1, which encodes 11β-hydroxysteroid
dehydrogenase type 1 (11β-HSD-1) [1]. Inactivating muta-
tions in 11β-HSD-1 cause androgenic precursors to accu-
mulate in the adrenal gland, resulting in congenital adrenal
hyperplasia (CAH), a condition that can virilize females in
utero [28]. Consistent with the hypothesized programming
effects of prenatal androgens, females with CAH score sig-
nificantly higher than their unaffected sisters on the Autism
Spectrum Quotient (AQ), a self-report measure of autistic
traits [29].
A few studies have implicated hyperandrogenemia in
ASC. However, it is not clear whether the rise in andro-
gens is mediated by the gonads or the adrenals, or is found
in both sexes and across the whole of the lifespan. Testos-
terone, luteinizing hormone (LH) [7] and androstenedione
[6] are all elevated in women with ASC, but of these only
androstenedione is also elevated in men with ASC [6,7].
DHEA-S, DHEA [30] and testosterone [31] are elevated in
pre-pubertal or pubertal ASC males, but are decreased or
unchanged relative to controls in adolescent and adult
ASC males [6,32-34].
Animal models of prenatal androgenization (PNA) con-
sistently produce a hyperandrogenic, anovulatory, insulin-
resistant, viscerally obese phenotype [16], with epigenetic
changes in genes involved in ovarian folliculogenesis, insu-
lin signaling, and the HPG axis [35]. However, the effects
of PNA on the timing of puberty remain unclear. For ex-
ample, rhesus macaques with PNA exhibit delayed pu-
berty, but mice with PNA exhibit early puberty [36];
additionally, pubertal androgen levels and nutrition affect
the timing of menarche as well [37]. Similarly, PCOS is
associated with both early puberty [38,39] and delayed
menarche [40].
While hyperandrogenemia is correlated with a set of
reproductive symptoms, testosterone is only one of a series
of inter-related metabolites that includes the primary ovar-
ian hormones progesterone and estradiol. Consequently,
variation in the steroidogenic pathway in females with
ASC would be expected to also result in symptoms or
conditions related to abnormal levels of progesterone and/
or estradiol, such as endometriosis [41] or steroid-sensitive
cancers. Additionally, women with ASC would be expected
to have increased susceptibility to psychiatric and neuro-
logical conditions mediated by gonadal hormones, such as
premenstrual dysphoric disorder (PMDD) [42], anorexia
[43], or epilepsy [44].
Previously, we reported significant increases in the
frequency of steroid hormone-associated and sex-linked
conditions in women with ASC and in mothers of chil-
dren with ASC [45]. In the current study, we (1) test ifthese findings replicate in a larger sample, and (2) exam-
ine the patterns of reported reproductive symptoms and
conditions to understand if differences exist between
subgroups of women with and without ASC.
Methods
Participants
We recruited two groups of participants from the
Cambridge Autism Research Centre Database, which con-
sists of volunteers registered either at the Autism Research
Centre (www.autismresearchcentre.com) or Cambridge Psy-
chology (www.cambridgepsychology.com) volunteer web-
sites. As a check on the difference between the groups, we
administered the AQ [46].
Women with an autism spectrum condition
In total, 415 women with an ASC participated in the
survey. These comprised 260 women with Asperger Syn-
drome, 27 with high functioning autism, and 128 women
with an ASC that was not further specified. The mean
(±SD) age of the ASC group was 36.39 ± 11.98 years.
The mean AQ (±SD) of the respondents with ASC who
also completed the AQ (n = 379) was 35.54 ± 10.96, in
line with previous studies [46]. Additionally, participants
were asked for the qualification of the individual who di-
agnosed them (for example, psychiatrist, clinical psych-
ologist), the clinic where the diagnosis was made, and
the date of their diagnosis.
Female controls
In total, 415 women without an ASC participated in the
study, after exclusions. We excluded women with an AQ
greater than 1 SD (AQ ≥23) above the population mean
from previously reported samples, following established
methods in previous studies [47], to ensure undiagnosed
cases of ASC were excluded from the control group. We
also excluded participants who reported having a relative
with an ASC to minimize the likelihood that the control
group might have a Broader Autism Phenotype [47].
The control participants had a mean age of 39.96 ±
11.92 years.
Ethics
The Cambridge Autism Research Centre Database received
ethical approval from the Psychology Research Ethics
Committee at the University of Cambridge.
Measures
All participants took the Testosterone-related Medical
Questionnaire (TMQ), which has previously been used
[45] (see Additional file 1: Supplementary Appendix 1).
The TMQ was completed online. We assumed consent
on the return of a completed questionnaire.
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We computed frequency tables for women with ASC
versus control women for each item on the TMQ. Previ-
ous research has shown that rates of contraceptive pill
(CP) use are lower among women with an ASC [45].
Additionally, the CP can reduce many of the symptoms
on the TMQ. In order to ensure that CP use was not
affecting symptoms reported by participants, we used
log-linear analysis to check for three-way interactions
between group, contraceptive use, and reproductive or
sex steroid-related items (PCOS, premenstrual syndrome
(PMS), excessive menstrual bleeding, hirsutism, amenor-
rhea (irregular menstrual cycle), dysmenorrhea (un-
usually painful periods) and severe acne) and two-way
interactions between contraceptive use and each symp-
tom. Only parous women were considered on obstetric
items (miscarriage, pre-eclampsia, and difficulty conceiv-
ing). Unadjusted odds ratios were calculated from each
two-by-two frequency table. Fisher’s one-sided exact test
was used to calculate significance, unless otherwise noted.
SPSS was used to calculate all frequency-based statistics
SPSS Statistics version 21, IBM, IBM Corporation, 1 New
Orchard Road,Armonk, New York 10504-1722, United
States.
As the questionnaire was designed to measure endo-
crine symptoms and conditions, we surmise that re-
sponse patterns on the questionnaire reflect underlying
endocrine status. For example, the likelihood of a par-
ticipant reporting amenorrhea is linked to her likelihood
of reporting hirsutism, as both symptoms are associated
with an increased free androgen index [48]. Latent class
analysis (LCA) assumes that an individual’s responses on
a series of observed variables can be explained by an in-
dividual’s status on an unmeasured, or latent, categorical
variable. LCA identifies high frequency response pat-
terns on the series of observed variables, and these re-
sponse patterns are used to draw conclusions about the
discrete subpopulations, or latent classes, within the
study population. By using LCA, we can explore group
differences across a profile of steroid-related symptoms
or conditions.
LCA is often described as a categorical cousin of factor
analysis. However, unlike factor analysis, it maintains a
“person-centric”, rather than a “variable-centric”, approach.
For each subpopulation identified, LCA returns item-
specific conditional probabilities describing the likelihood
that an individual would respond positively to specific
items given membership in a given latent subpopulation.
These conditional probabilities are used to characterize the
subpopulations. LCA uses an expectation-maximization
algorithm to determine the prevalence of latent classes
within the population and the posterior probabilities de-
scribing class membership. By applying LCA to our data,
we aimed to uncover interpretable clusters of individualswith similar steroid-related symptoms, and the prevalence
of these clusters in women with and without autism.
Variables that may influence class membership can be
entered as covariates in LCA. We entered body mass
index (BMI) and contraceptive use as covariates, as both
adiposity [49] and contraceptive use affect hormonal
levels. Including BMI as a covariate reduced our sample
size slightly to 342 participants with ASC, and 402 con-
trol participants. The Lo-Mendell-Rubin (LMR) test was
used to compare models with k and k-1 latent classes,
and the Akaike Information Criterion (AIC) and Bayesian
Information Criterion (BIC) were used to compare model
fit (Additional file 2). We used multiple-group LCA to
compare women with ASC to controls, allowing us to
detect both qualitative differences (that is, number of sub-
populations, conditional item-response probabilities for
each subpopulation) and quantitative differences (that is,
differences in subpopulation prevalence) between groups.
Likelihood ratio tests (LRTs) were used to detect signifi-
cant improvements in model fit as a result of including
‘ASC diagnosis’ as a grouping variable. All latent class
modeling was done with MPlus Version 7 Muthén &
Muthén, 3463 Stoner Avenue, Los Angeles, CA 90066.
Results
Frequency differences on each item are shown in Table 1.
Prior to assessing frequency differences between the
groups, we used log-linear analysis to ascertain if contra-
ceptive use was associated with any of the conditions
and ASC diagnosis. There were no three-way interac-
tions between ASC diagnosis, contraceptive use, and any
steroid-related symptom or diagnosis, but we found sig-
nificant interactions between contraceptive use and PCOS,
PMS, menorrhagia, and severe acne. Subsequently, we re-
port rates of PCOS, PMS, menorrhagia, and severe acne
with respect to contraceptive use.
Significant differences between women with ASC and
controls were found for self-reported rates of anorexia
(P < 0.0001), epilepsy (P = 0.016), and cardiac conditions
(excluding cardiac arrhythmia) (P = 0.012). Additionally,
self-report rates of testosterone-related symptoms in-
cluding irregular menstrual cycles (P = 0.0002) and un-
usually painful periods (P < 0.0001) were higher among
women with ASCs than controls. Self-reported rates of
hirsutism, a characteristic feature of PCOS, were hig-
her among women with ASC, though the trend did
not reach significance (P = 0.089). Among contraceptive
users, women with ASC reported PMS (P = 0.001) and
menorrhagia (P = 0.019) significantly more frequently
than controls. However, among non-contraceptive users,
significantly more women with an ASC than controls
reported having severe acne (P = 0.002). There was also
a near significant difference in acne (P = 0.053) between
women with an ASC who used the CP and controls who
Table 1 Frequencies of reproductive and sex-linked symptoms and conditions among women with autism spectrum
conditions and controls
Condition or symptom Women with ASC (n = 415) Controls (n = 415) Unadjusted
odds ratio
(95% CI)
P value
(Fisher's
exact test,
one-sided)
(sample size, if different from above) (sample size, if different from above)
n (%) n (%)
Sex-linked conditions
Anorexia 33 (8.0%) 10 (2.4%) 3.50 (1.70-7.20) 0.000
Congenital adrenal hyperplasia 1 (0.2%) 0 (0.0%) - 0.500
Diabetes 10 (2.4%) 14 (3.4%) 0.71 (0.31-1.61) 0.268
Epilepsy 17 (4.1%) 6 (1.4%) 2.91 (1.14-7.46) 0.016
Any hormonal medical condition 43 (10.4%) 35 (8.4%) 1.23 (0.79-2.01) 0.203
Cardiac condition 16 (3.9%) 5 (1.2%) 3.29 (1.19-9.06) 0.012
Thyroid condition 35 (8.4%) 35 (8.4%) 1.00 (0.61-1.63) 0.550
Penicillin allergy 38 (9.2%) 37 (8.9%) 1.03 (0.64-1.66) 0.500
Reproductive or sex steroid-related symptoms or conditions
Hirsutism 76 (18.3%) 61 (14.7%) 1.30 (0.90-1.88) 0.089
Irregular menstrual cycle 192 (46.3%) 141 (34.0%) 1.673 (1.26-2.21) 0.0002
Unusually painful periods 163 (39.3%) 109 (26.3%) 1.82 (1.35-2.44) 0.00004
Polycystic ovary syndrome
Contraceptive pill users 33 (11.8%) 47 (14.4%) 0.80 (0.50-1.29) 0.212
279 327
Contraceptive pill non-users 11 (10.2%) 4 (4.7%) 2.296 (0.70-7.49) 0.126
108 85
Pre-menstrual syndrome
Contraceptive pill users 67 (24.0%) 45 (13.8%) 1.98 (1.30-3.01) 0.001
279 327
Contraceptive pill non-users 12 (11.1%) 7 (8.2%) 1.39 (0.52-3.71) 0.339
108 85
Excessive menstrual bleeding
Contraceptive pill users 94 (33.7%) 84 (25.7%) 1.47 (1.04-2.09) 0.019
279 327
Non-contraceptive pill users 22 (20.4%) 14 (16.5%) 1.30 (0.62-2.72) 0.308
108 85
Severe acne
Contraceptive pill users 49 (17.6%) 41 (12.5%) 1.49 (0.95-2.33) 0.053
279 327
Non-contraceptive pill users 23 (21.3%) 5 (5.9%) 4.33 (1.57-11.94) 0.002
108 85
Timing of puberty
Delayed puberty 4 (1.0%) 2 (0.5%) 2.01 (0.37-11.03) 0.343
Precocious puberty 13 (3.1%) 2 (0.5%) 6.68 (1.50-29.78) 0.003
Early growth spurt 84 (20.2%) 53 (12.8%) 1.73 (1.19-2.521) 0.002
Periods after 16 years 28 (6.7%) 19 (4.6%) 1.51 (0.83-2.75) 0.115
Periods before 10 years 34 (8.2%) 23 (5.5%) 1.52 (0.88-2.63) 0.085
Reproductive cancers
Breast cancer 17 (4.1%) 15 (3.6%) 1.14 (0.56-2.31) 0.429
Family history of breast cancer 97 (23.4%) 106 (25.5%) 0.89 (0.65-1.22) 0.259
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Table 1 Frequencies of reproductive and sex-linked symptoms and conditions among women with autism spectrum
conditions and controls (Continued)
Ovarian cancer 9 (2.2%) 12 (2.9%) 0.74 (0.31-1.79) 0.330
Family history of ovarian cancer 49 (11.8%) 41 (9.9%) 1.22 (0.79-1.90) 0.217
Family history prostate cancer 39 (9.4%) 44 (10.6%) 0.88 (0.56-1.34) 0.322
Uterine cancer 17 (4.1%) 12 (2.9%) 1.43 (0.68-3.04) 0.225
Family history uterine cancer 43 (10.4%) 34 (8.2%) 1.30 (0.81-2.08) 0.169
Gender and sexuality
Tomboyism 371 404
252 (67.9%) 171 (42.3%) 2.885 0.0000
Gender dysphoria 320 396
12 (3.8%) 1 (0.3%) 15.39 0.0004
Sexual preference
414 415 0.000*
Male 261 (63.0%) 369 (88.9%)
Female 48 (11.6%) 28 (6.7%)
Both 57 (13.8%) 18 (4.3%)
Neither 48 (11.6%) 0 (0.0%)
Transsexual 102 52
12 (11.8%) 1 (1.9%) 6.80 (0.86-53.82) 0.030
Obstetric conditions ASC (parous) Controls (parous)
185 264
Miscarriage 56 (30.3%) 65 (24.6%) 1.33 (0.87-2.02) 0.111
Pre-eclampsia 12 (6.5%) 17 (6.4%) 1.01 (0.47-2.16) 0.565
Difficulty conceiving 25 (13.5%) 51 (19.3%) 0.65 (0.39-1.10) 0.068
*A chi-squared statistic was calculated instead of using Fisher’s exact test. P values shown in bold are significant (P < 0.05). ASC, autism spectrum conditions.
Table 2 Information criteria for models of k classes and
Lo-Mendell-Rubin test for improvement between models
with k and k-1 classes
k classes df -log
likelihood
AIC BIC LMR test
P value
1 8 -6,424.359 12,878.718 12,949.54
2 21 -2,906.206 5,862.413 5,977.781 0.0000
3 30 -2,869.814 5,817.628 5,997.602 0.6174
The lowest values on the information criteria indicate the best model (shown
in bold), weighing absolute model fit and number of estimated parameters. A
description of the two and three class models can be found in Additional file 1:
Table S1. AIC, Akaike Information Criterion; BIC, Bayesian Information Criterion;
df, degrees of freedom; LMR, Lo-Mendell-Rubin. P value in bold indicates
significance P < 0.05).
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and early growth spurt (P = 0.002) were significantly dif-
ferent between women with ASC and controls, while
there was a trend towards significance in menarche prior
to 10 years of age (P = 0.085). No differences in rates of
hormone-responsive cancers (ovarian, uterine, or breast) or
family history of hormone-responsive cancers (ovarian, uter-
ine, breast, or prostate) were found between participants
with ASC and controls. Similarly, no differences in gesta-
tional complications were found between parous women
with an ASC (n = 185) and parous controls (n = 264).
Questions regarding gender identity and sexual orienta-
tion were optional; fewer participants responded to items
on ‘tomboyism’, gender identity disorder, and transse-
xualism. Significantly more women with an ASC (n = 371)
than controls (n = 404) reported being a ‘tomboy’ during
childhood (P < 0.0001). Different self-report frequencies of
gender identity disorder (also gender dysphoria) (P =
0.0004; ASC n = 320, control n = 396), and transsexualism
(P = 0.030; ASC n = 102, control n = 52) were found be-
tween women with ASC and controls. Finally, participant
sexual orientation (chi-squared; P < 0.001) differed signifi-
cantly between women with ASC (n = 414) and controls(n = 415), with more women with ASC reporting bisexual-
ism or lesbianism than among controls.
Latent class analysis results
Determining the correct number of latent classes is the
first step in LCA. To chose the correct number of latent
classes for our analysis, we minimized the AIC and BIC by
choosing a model with k classes, and we used the LMR
test to verify that the model with k classes fit better than
the model with k-1 classes (Table 2). The three-class
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the lowest BIC. The BIC tends to outperform the AIC at
identifying the best model when the sample size is large in
LCA [50]. The LMR test supported the two-class model,
as the three-class model did not fit better than the two-
class model (P = 0.6174). Consequently, we determined
that the two-class model was the best representative of the
true latent class structure, and used a k = 2 model for our
multigroup LCA. Clear divisions existed between the clas-
ses, with one class having low and the other class having
high probabilities of reporting early growth spurt, PCOS,
hirsutism, irregular menstrual cycles, painful periods, se-
vere acne, and excessive menstrual bleeding (Figure 1).
Because the intensity of sex steroid-related symptoms
can vary with adiposity and hormonal CP use, we in-
cluded BMI and CP use as covariates in our model. BMI
was significantly associated with membership in the la-
tent class characterized by increased risk of steroid-
related symptoms and conditions (which we deemed the
‘steroidopathic’ class) (βBMI = 0.118; P < 0.001), but CP
use was not (βCP = 0.277; P = 0.264). Similar results were
found for BMI and CP use in all models.
In order to ascertain whether the prevalence and char-
acteristics of the latent classes varied by ASC diagnosis,
we performed a two-class LCA comparing women withFigure 1 Class-dependent conditional probabilities for Testosterone-r
latent classes. This figure demonstrates the strong separation between the l
over 500 bootstrap replications. For polycystic ovary syndrome (PCOS), the co
spectrum condition (ASC)-steroidopathic’ latent class, and for the ‘control-ster
differences on responses to this item. *P < 0.05, **P < 0.01, ***P < 0.001, significASC to controls. First, we compared an unconstrained
model where both the number of women in each latent
class and the item-response patterns within the latent
classes were allowed to vary by diagnosis, to a semi-
constrained model where only the number of women in
each latent class was allowed to vary by diagnosis. This
tested if the characteristics of the latent classes were
similar between groups; no significant improvement in
model fit was detected by allowing the item-response
patterns to vary by diagnosis (ΔG2 = 20.309, df = 22,
P = 0.0625, information criteria, Table 3; likelihood ratio
tests, Table 4). However, the trend towards significance
prompted us to further explore item-response posterior
probabilities between groups. Subsequently, a Wald par-
ameter test revealed that the difference in the posterior
probability of reporting PCOS was significant (chi-
squared = 11.743, df = 2, P = 0.0028); no other posterior
probabilities differed significantly between groups. Allow-
ing the posterior probability of reporting PCOS to vary
while other parameters were held equal between groups
improved all information criteria (Table 3), and signifi-
cantly improved model fit (LRT; ΔG2 = 6.673, df = 2, P =
0.0178) (Table 4).
When characteristics of the latent classes are similar
between groups, we can restrain item-specific parameterselated Medical Questionnaire items for steroidopathic and typical
atent classes. Error bars represent 95% confidence intervals generated
nditional probability is given for the ‘typical’ latent class, the ‘autism
oidopathic’ latent class, in order to demonstrate the between-group
ant difference between classes.
Table 3 Information criteria for multi-group latent class
analysis models
Model -log likelihood AIC BIC
Unconstrained -3,390.623 6,879.246 7,105.367
Semiconstrained -3,410.932 6,875.863 7,000.461
Semiconstrained, PCOS
posterior probability variable
-3,404.259 6,866.517 7,000.344
Fully constrained -3,420.879 6,893.758 7,013.74
Fully constrained, PCOS
posterior probability variable
-3,417.608 6,891.216 7,020.428
The lowest values on the information criteria indicate the best model (shown
in bold), weighing absolute model fit and number of estimated parameters. In
the unconstrained model, both conditional probabilities and latent class
prevalences are allowed to vary by diagnostic group; in the semi-constrained
model, only latent class prevalences are allowed to vary by group; in the fully
constrained model, both diagnositic groups are forced to have the same latent
class prevalences and the same item-response conditional probabilities. Further
discussion of model comparison can be found in Additional file 1, and 5-fold cross
validated loglikelihood, AIC, and BIC values for these models can be found in
Additional file 2. AIC, Akaike Information Criterion; BIC, Bayesian Information
Criterion; df, degrees of freedom; PCOS, polycystic ovary syndrome.
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groups. However, because the PCOS parameter varied be-
tween groups, we allowed the groups to vary on this single
parameter while holding the others constant (Figure 1). In
order to test if the latent class prevalences differed be-
tween groups, we compared the semi-constrained model
(only prevalences allowed to differ) to a fully-constrained
model where latent class prevalences were forced to be
the same for both the ASC and control groups. The semi-
constrained model was a significantly better fit, indicating
differences in latent class prevalence between groups
(LRT; ΔG2 = 13.349, df = 1, P = 0.0001) (Table 4). We con-
clude that the primary difference between the ASC group
and the control group was latent class prevalence: the
model assigned 48% of individuals with ASC and 25% of
controls to the ‘steroidopathic’ latent class (Table 5).
Discussion
In line with previous results [45], we detected higher
rates of items on the TMQ associated with atypical levels
of, or atypical responses to, sex steroids among women
with ASC. In particular, we confirmed higher frequencies
of epilepsy, amenorrhea, dysmenorrhea, severe acne,
gender dysphoria, and transsexualism, and differences in
sexual preference in a large sample of women with ASC.Table 4 Likelihood ratio tests used to compare model fit betw
H0 Model H1 Model Δ
Semiconstrained Unconstrained 20
Semiconstrained Semiconstrained, PCOS
posterior probability variable
6.6
Fully constrained, PCOS
posterior probability variable
Semiconstrained, PCOS
posterior probability variable
13
P value in bold indicates significance P < 0.05). df, degrees of freedom; PCOS, polycyAdditionally, we detected significantly higher rates of
anorexia, cardiac conditions, menorrhagia, PMS, preco-
cious puberty, and early growth spurt among women
with ASC. We did not replicate significant differences in
PCOS diagnosis, delayed puberty, and hirsutism between
women with ASC and controls.
In order to understand if equal rates of steroid-related
conditions occurred between women with ASC and con-
trols, we conducted a multi-group LCA on 11 items ex-
plicitly linked to sex steroids. In both women with ASC
and controls, two latent classes (typical and steroido-
pathic) emerged; a higher percentage of women with
ASC fell into the steroidopathic class than did controls.
Increased membership of women with ASC in the ster-
oidopathic class, which had high posterior probabilities
for symptoms known to reflect circulating androgen
levels, is consistent with elevated LH and bioavailable
testosterone in women with ASC [7]. Within the steroi-
dopathic groups, conditional probabilities on all items
were equivalent between ASC/steroidopathic and con-
trol/steroidopathic, with the notable exception of PCOS.
Because the steroidopathic groups were homogenous
with respect to all other symptoms surveyed, we believe
this is a diagnostic rather than a biological difference. It
is possible that the reduced marriage rate and fecundity
among women with ASC [51,52] make them less likely
to have a diagnosis of PCOS as they may be less likely to
have sought infertility treatment, contributing to pos-
sible under-detection of PCOS within this population.
PCOS only accounts for 85% of cases of clinical hyper-
androgenemia within the general population, and the
different conditional probabilities for PCOS diagnosis
between the two steroidopathic groups could also reflect
an increase in difficult-to-detect hyperandrogenic condi-
tions such as non-classical congenital adrenal hyperpla-
sia among women with ASC [53].
Puberty and prenatal androgen exposure
The increased sample size of this follow-up study allowed
us to detect differences in the timing of puberty (‘preco-
cious puberty’ and ‘early growth spurt’) between women
with autism and controls. Adrenarche, or adrenal puberty,
is marked by an increase in the adrenal androgens DHEA
and androstenedione; elevation of adrenal androgens iseen H0 and H1 models
G2 df P value Null hypothesis (H0)
.309 22 0.0625 Latent class characteristics
equal between groups
73 2 0.0178 Constraining the PCOS parameter
does not affect model fit
.349 1 0.0001 Latent class prevalences
equal between groups
stic ovary syndrome.
Table 5 Class prevalences and class-dependent conditional
probabilities for conditions and symptoms relating to steroids
Latent class membership
Steroidopathic Typical
ASC 48% 52%
Control 25% 75%
Posterior probabilities Steroidopathic Typical
Conditional
probability
(95% CI)
Conditional
probability
(95% CI)
Delayed puberty 0.01 (0.00-0.03) 0.01 (0.00-0.02)
Periods after 16 years 0.07 (0.04-0.11) 0.05 (0.03-0.06)
Periods before 10 years 0.12 (0.08-0.17) 0.03 (0.01-0.06)
Precocious puberty 0.05 (0.02-0.08) 0.00 (0.00-0.00)
Early growth spurt 0.26 (0.20-0.33) 0.10 (0.07-0.14)
PCOS (ASC/control) 0.24 (0.16-0.33)/
0.47 (0.35-0.64)
0.00 (0.00-0.00)
Hirsutism 0.40 (0.32-0.48) 0.04 (0.02-0.07)
Irregular menstrual cycle 0.72 (0.63-0.80) 0.22 (0.18-0.27)
Painful periods 0.61 (0.54-0.68) 0.16 (0.11-0.21)
Acne 0.22 (0.17-0.28) 0.11 (0.08-0.15)
Excessive menstrual bleeding 0.56 (0.48-0.63) 0.10 (0.05-0.15)
Percentages of the ASC and control groups assigned to the steroidopathic and
typical latent classes (top) and conditional probabilities for Testosterone-related
Medical Questionnaire items by latent class (bottom). Bootstrapped (500 starts)
95% confidence intervals of parameter estimates in brackets. ASC, autism spectrum
conditions; PCOS, polycystic ovary syndrome.
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which responds to insulin-like growth factors [56,57]. Adre-
narche occurs prematurely in low birth weight children,
females who later develop PCOS, and daughters of females
with PCOS [39], suggesting prenatal programming of adrenal
androgen synthesis. Women with ASC reported precocious
puberty more frequently than controls. Unfortunately, the
questionnaire did not distinguish between central, or HPG-
dependent precocious puberty, and pseudo-precocious pu-
berty, typically due to adrenal androgen secretion [58]. We
are currently collecting data on the timing of various adrenal
(for example, pubic hair growth) and gonadal (for example,
breast development) markers of puberty in this group.
Activation of the HPG axis occurs at gonadarche (in
human Caucasian girls beginning around age 9 to 10 years),
as increasing gonadotropin-releasing hormone (GnRH) pulse
frequency and amplitude elevate circulating sex steroids,
leading to physiological changes including menarche (which
has a typical age of onset of 12 to 13 years in Caucasian
girls). Previous studies report a delay in menarche among
women with ASC [45,59]; however, the current study found
an early growth spurt and accelerated menarche in women
with ASC, consistent with findings of both early [55] and
delayed [40] menarche in PCOS. Decreased 2D:4D ratio is
associated with delayed menarche in the general population[60,61], but adiposity and low birth weight - which can both
be induced by maternal hyperandrogenemia - tend to accel-
erate puberty, and this pattern is more frequently observed
in clinical PCOS populations [62].
Because we allowed latent class membership to co-
vary on BMI, it is unsurprising that the posterior prob-
abilities for early growth spurt and periods before
10 years of age are increased in the steroidogenic class
while the posterior probabilities for periods after 16 years
of age and delayed puberty are relatively similar to the
typical class, as we have incorporated adiposity in our
model. In hyperinsulinemic hyperandrogenemia, androgens
accelerate desensitization of GnRH neurons to negative
feedback by progesterone, causing LH-producing high
frequency GnRH pulses to occur earlier in life [63,64]. The
balance between androgens and progesterone may be medi-
ated by γ-aminobutyric acid (GABA)A receptors on pre-
synaptic GABAergic and postsynaptic GnRH neurons, as
progesterone administration to ovariectomized females
results in decreased GABAergic post-synaptic current, but
dihydrotestosterone administration raises GABAergic post-
synaptic current and frequency, eliminating the effects of
progesterone and resulting in elevated LH [65,66]. PNA
increases connectivity between GABAergic and GnRH
neurons, and dysregulates AMPK-mediated glucose sensing
in GnRH neurons, causing elevated GnRH pulse frequency
and amplitude throughout the lifespan [67,68].
Atypical sensitivities to sex steroids in autism spectrum
conditions?
In addition to the reproductive symptoms analyzed in the
LCA, we also uncovered significant differences in neuro-
logical and psychiatric states associated with sex steroids
between women with ASC and controls. Seizure activity is
exacerbated by menstrual cycle phase in approximately
40% of women with epilepsy [69]. As progesterone, estra-
diol, and the sex steroid metabolites allopregnanolone and
androstenedione modulate neuronal excitation, fluctua-
tions between pro- and anti-convulsant neurosteroids dur-
ing the menstrual cycle contribute to epileptogenesis [70].
Consistent with the involvement of the sex steroids in cat-
amenial epilepsy (a form of epilepsy that is sex hormone-
sensitive), there is an increased prevalence of PCOS and
other reproductive disorders among women with epilepsy
[71]. However, the relationship between female reproduct-
ive disorders and epilepsy is complex, as both seizure
activity [72] and valproate use [71] can disrupt the HPG
axis. While the co-morbidity of epilepsy and autism is well
established [73], few efforts have been made to explain the
increased risk for epilepsy among females with autism [74]
and the peak prevalence of epilepsy at adolescence [73]
among individuals with ASC.
Neurosteroid modulation of GABAA receptors offers
an intriguing potential connection between autism risk,
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includes seizures and social deficits can be established in
mice through selective haplodeletion of the Na+V1.1 ion
channel-encoding SCN1A gene in forebrain GABAergic
interneurons [75]. Furthermore, this phenotype can be
rescued with clonazepam, a positive allosteric modulator
of the GABAA receptor that shares a binding site with
allopregnanolone [75,76]. As the most neurosteroid-
sensitive GABAA subunit, δ, is downregulated in
response to chronic elevations of progesterone and/or
allopregnanolone, changes in circulating neurosteroids
during puberty [77] and during the menstrual cycle could
increase risk of GABAA-dependent epilepsy among women
and adolescents with ASC. Interestingly, allopregnanolone
increases in response to both adrenocorticotropic hormone
and GnRH [78], implicating both the adrenals and ovaries
in its production; however, adrenocorticotropic hormone-
stimulated allopregnanolone levels are decreased in women
with PCOS [79], suggesting dysregulation of allopregnano-
lone in this population. The convergence between ASC, sex
steroid metabolism, epilepsy, and GABAA could be a target
for future research, especially given findings that prenatal
testosterone programs GABAergic signaling [80], particu-
larly in sexually dimorphic areas that control reproductive
function [67].
Similar to epilepsy, the increased prevalence of PMS
(PMDD) and anorexia in women with ASC may repre-
sent shared psychiatric susceptibilities to hormones ra-
ther than shared alterations in sex steroids per se.
Women with PMDD may have a severe experience of
normal fluctuations in emotional processing and cogni-
tion across the menstrual cycle, and estrogen modification
of serotonergic circuits and allopregnanolone modification
of GABAergic signaling have both been implicated in the
etiology of PMDD [81]. An increased prevalence of an-
orexia among women with ASC is consistent with sugges-
tions that anorexia may have a similar cognitive phenotype
to, and share risk factors with, ASC [82]. Individuals with
anorexia score significantly higher than controls on the
AQ [83,84], have similar deficits to individuals with ASC in
executive function and central coherence [85], and first-
degree family members of anorexic individuals report a
higher number of DSM-IV pervasive developmental delay
symptoms [86].
Women with ASC reported masculine sex-typical
childhood behaviors (‘tomboyism’), gender dysphoria,
and non-heterosexual orientations significantly more fre-
quently than controls, consistent with the organizational
effects of prenatal testosterone on sexually dimorphic
brain structures, and sexual behaviors [87]. The increased
frequency of cardiac conditions among women with ASC
may reflect abnormalities in calcium channels that could
affect both neurological and cardiac development, as seen
in Timothy Syndrome [88].Conclusions
We find increased frequencies of conditions linked to
atypical steroid metabolism and atypical psychological
responses to steroids in females with ASC. Additionally,
we find that women with ASC are significantly more
likely to belong to a ‘steroidopathic’ group characterized
by reproductive dysfunction, hyperandrogenism, and
atypical pubertal development, despite being less likely
to report a diagnosis of PCOS than controls. Given the
shared hypothesis of prenatal androgen exposure for
both ASC and PCOS, further elucidating the cognitive
phenotype of women with PCOS and the reproductive
phenotype of women with ASC could offer insight into
both conditions.
Additional files
Additional file 1: Expanded Methods. Expanded discussion of latent
class modeling. Expanded Results: Expanded results of latent class
model fit. Table S1: Posterior probabilites of two- and three-class models.
Appendix 1: Testosterone-related Medical Questionnaire. Figure S1:
Strong agreement on item posterior probabilities within groups and classes.
Additional file 2: Model Validation. Results of five-fold cross validation.
Abbreviations
11β-HSD-1: 11β-hydroxysteroid dehydrogenase type 1; AIC: Akaike
Information Criterion; AQ: Autism Spectrum Quotient; ASC: autism spectrum
conditions; BIC: Bayesian Information Criterion; BMI: body mass index;
CAH: congenital adrenal hyperplasia; CP: contraceptive pill; FT: fetal
testosterone; GABA: γ-aminobutyric acid; GnRH: gonadotropin-releasing
hormone; HPG: hypothalamic-pituitary-gonadal; LCA: latent class analysisLH,
luteinizing hormone; LMR: Lo-Mendell-Rubin; LRT: likelihood ratio test;
PCOS: polycystic ovary syndrome; PMDD: premenstrual dysphoric disorder;
PMS: premenstrual syndrome; PNA: prenatal androgenization;
TMQ: Testosterone-related Medical Questionnaire.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
AP: data collection and analysis, manuscript writing and final approval of the
manuscript. SC: data collection, critical revision and final approval of the
manuscript. BA: conception and design, critical revision and final approval of
the manuscript. SB-C: conception and design, financial support, manuscript
writing, final approval of the manuscript. All authors read and approved the
final manuscript.
Acknowledgments
We are grateful to Mike Lombardo, Liliana Ruta, Bhismadev Chakrabarti,
Meng-Chuan Lai, Melissa Hines, Michelle St Clair, Rachel Grove, and Ieuan
Hughes for helpful discussions. AP was supported by a PhD studentship from
Trinity College, Cambridge, and SB-C was supported by the MRC, the Autism
Research Trust, and the Wellcome Trust during the period of this work. This
project was conducted in association with the NIHR CLAHRC for Cambridgeshire
and Peterborough NHS Foundation Trust.
Author details
1Autism Research Centre, Department of Psychiatry, University of Cambridge,
Douglas House, 18B Trumpington Road, Cambridge CB2 8AH, UK.
2Department of Psychology and Behavioural Sciences, Coventry University,
James Starley Building, Cox Street, Coventry CV1 5LW, UK. 3Department of
Psychology, University of Edinburgh, 7 George Square, Edinburgh EH8 9 AD,
UK. 4CLASS Clinic, Cambridgeshire and Peterborough Mental Health
Pohl et al. Molecular Autism 2014, 5:27 Page 10 of 12
http://www.molecularautism.com/content/5/1/27Foundation NHS Trust, The Chitra Sethia Autism Centre, The Gatehouse,
Fulborn Hospital, Fulborn, Cambridge CB21 5EF, UK.
Received: 8 August 2013 Accepted: 10 March 2014
Published: 9 April 2014References
1. Chakrabarti B, Dudbridge F, Kent L, Wheelwright S, Hill-Cawthorne G, Allison
C, Banerjee-Basu S, Baron-Cohen S: Genes related to sex steroids, neural
growth, and social-emotional behavior are associated with autistic traits,
empathy, and Asperger syndrome. Autism Res 2009, 2:157–177.
2. Sarachana T, Xu M, Wu R-C, Hu VW: Sex hormones in autism: androgens
and estrogens differentially and reciprocally regulate RORA, a novel
candidate gene for autism. PLoS One 2011, 6:e17116.
3. Henningsson S, Jonsson L, Ljunggren E, Westberg L, Gillberg C, Råstam M,
Anckarsäter H, Nygren G, Landén M, Thuresson K, Betancur C, Leboyer M,
Gillberg C, Eriksson E, Melke J: Possible association between the androgen
receptor gene and autism spectrum disorder. Psychoneuroendocrinology
2009, 34:752–761.
4. Hu VW, Frank BC, Heine S, Lee NH, Quackenbush J: Gene expression
profiling of lymphoblastoid cell lines from monozygotic twins discordant
in severity of autism reveals differential regulation of neurologically
relevant genes. BMC Genomics 2006, 7:118.
5. Hu VW, Nguyen A, Kim KS, Steinberg ME, Sarachana T, Scully MA, Soldin SJ,
Luu T, Lee NH: Gene expression profiling of lymphoblasts from autistic
and nonaffected sib pairs: altered pathways in neuronal development
and steroid biosynthesis. PLoS One 2009, 4:e5775.
6. Ruta L, Ingudomnukul E, Taylor K, Chakrabarti B, Baron-Cohen S: Increased
serum androstenedione in adults with autism spectrum conditions.
Psychoneuroendocrinology 2011, 36:1154–1163.
7. Schwarz E, Guest PC, Rahmoune H, Wang L, Levin Y, Ingudomnukul E, Ruta L,
Kent L, Spain M, Baron-Cohen S, Bahn S: Sex-specific serum biomarker patterns
in adults with Asperger’s syndrome. Mol Psychiatr 2011, 16:1213–1220.
8. Auyeung B, Baron-Cohen S, Ashwin E, Knickmeyer RC, Taylor K, Hackett G:
Fetal testosterone and autistic traits. Br J Psychol 2009, 100:1–22.
9. De Bruin EI, De Nijs PF, Verheij F, Verhagen DH, Ferdinand RF: Autistic
features in girls from a psychiatric sample are strongly associated with a
low 2D:4D ratio. Autism 2009, 13:511–521.
10. Baron-Cohen S, Knickmeyer RC, Belmonte MK: Sex differences in the brain:
implications for explaining autism. Science 2005, 310:819–823.
11. Baron-Cohen S, Lombardo MV, Auyeung B, Ashwin E, Chakrabarti B,
Knickmeyer RC: Why are autism spectrum conditions more prevalent in
males? PLoS Biol 2011, 9:e1001081.
12. Lenz KM, Mccarthy MM: Organized for sex – steroid hormones and the
developing hypothalamus. Eur J Neurosci 2010, 32:2096–2104.
13. Lombardo MV, Ashwin E, Auyeung B, Chakrabarti B, Taylor K, Hackett G,
Bullmore ET, Baron-Cohen S: Fetal testosterone influences sexually
dimorphic gray matter in the human brain. J Neurosci 2012, 32:674–680.
14. Jansen HT, Hershey J, Mytinger A, Foster DL, Padmanabhan V:
Developmental programming: reproductive endocrinopathies in the
adult female sheep after prenatal testosterone treatment are reflected in
altered ontogeny of GnRH afferents. Endocrinology 2011, 152:4288–4297.
15. Manikkam M, Thompson RC, Herkimer C, Welch KB, Flak J, Karsch FJ,
Padmanabhan V: Developmental programming: impact of prenatal
testosterone excess on pre- and postnatal gonadotropin regulation in
sheep. Biol Reprod 2008, 78:648–660.
16. Dumesic DA, Abbott DH, Padmanabhan V: Polycystic ovary syndrome and
its developmental origins. Rev Endocr Metab Disord 2007, 8:127–141.
17. Beilin J, Ball EM, Favaloro JM, Zajac JD: Effect of the androgen receptor
CAG repeat polymorphism on transcriptional activity: specificity in
prostate and non-prostate cell lines. J Mol Endocrinol 2000, 25:85–96.
18. Ibáñez L, Ong KK, Mongan N, Jaaskelainen J, Marcos MV, Hughes IA, de
Zegher F, Dunger DB: Androgen receptor gene CAG repeat
polymorphism in the development of ovarian hyperandrogenism.
J Clin Endocrinol Metab 2003, 88:3333–3338.
19. Wang L, Li S, Zhao A, Tao T, Mao X, Zhang P, Liu W: The expression of sex
steroid synthesis and inactivation enzymes in subcutaneous adipose
tissue of PCOS patients. J Steroid Biochem Mol Biol 2012, 132:120–126.
20. Maliqueo M, Sun M, Johansson J, Benrick A, Labrie F, Svensson H, Lönn M,
Duleba AJ, Stener-Victorin E: Continuous administration of a p450 aromataseinhibitor induces polycystic ovary syndrome with a metabolic and endocrine
phenotype in female rats at adult age. Endocrinology 2013, 154:434–445.
21. Petry CJ, Ong KK, Michelmore KF, Artigas S, Wingate DL, Balen AH, de
Zegher F, Ibáñez L, Dunger DB: Association of aromatase (CYP 19) gene
variation with features of hyperandrogenism in two populations of
young women. Hum Reprod 2005, 20:1837–1843.
22. Solt LA, Kumar N, Nuhant P, Wang Y, Lauer JL, Liu J, Istrate MA, Kamenecka
TM, Roush WR, Vidović D, Schürer SC, Xu J, Wagoner G, Drew PD, Griffin PR,
Burris TP: Suppression of TH17 differentiation and autoimmunity by a
synthetic ROR ligand. Nature 2011, 472:491–494.
23. Demerath EW, Liu C, Franceschini N, Chen G, Palmer JR, Smith EN, Chen
CTL, Ambrosone CB, Arnold AM, Bandera EV, Berenson GS, Bernstein L,
Britton A, Cappola AR, Carlson CS, Chanock SJ, Chen W, Chen Z, Deming SL,
Elks CE, Evans MK, Gajdos Z, Henderson BE, Hu JJ, Ingles S, John EM, Kerr KF,
Kolonel LN, Le Marchand L, Lu X, et al: Genome-wide association study of
age at menarche in African-American women. Hum Mol Genet 2013,
22:3329–3346.
24. Pusalkar M, Meherji P, Gokral J, Chinnaraj S, Maitra A: CYP11A1 and CYP17
promoter polymorphisms associate with hyperandrogenemia in
polycystic ovary syndrome. Fertil Steril 2009, 92:653–659.
25. Nelson VL, Qin KN, Rosenfield RL, Wood JR, Penning TM, Legro RS, Strauss
JF, McAllister JM: The biochemical basis for increased testosterone
production in theca cells propagated from patients with polycystic ovary
syndrome. J Clin Endocrinol Metab 2001, 86:5925–5933.
26. Munir I, Yen H-W, Geller DH, Torbati D, Bierden RM, Weitsman SR, Agarwal SK,
Magoffin DA: Insulin augmentation of 17alpha-hydroxylase activity is mediated
by phosphatidyl inositol 3-kinase but not extracellular signal-regulated
kinase-1/2 in human ovarian theca cells. Endocrinology 2004, 145:175–183.
27. Li H, Chen Y, Yan L, Qiao J: Increased expression of P450scc and CYP17 in
development of endogenous hyperandrogenism in a rat model of PCOS.
Endocrine 2013, 43:184–190.
28. Zhao L, Han S, Tian H: Progress in molecular-genetic studies on congenital
adrenal hyperplasia due to 11beta-hydroxylase deficiency. World J Pediatr
2008, 4:85–90.
29. Knickmeyer RC, Baron-Cohen S, Fane BA, Wheelwright S, Mathews GA, Conway
GS, Brook CGD, Hines M: Androgens and autistic traits: a study of individuals
with congenital adrenal hyperplasia. Horm Behav 2006, 50:148–153.
30. Mills JL, Hediger ML, Molloy CA, Chrousos GP, Manning-Courtney P, Yu KF,
Brasington M, England LJ: Elevated levels of growth-related hormones in
autism and autism spectrum disorder. Clin Endocrinol (Oxf ) 2007, 67:230–237.
31. Schmidtova E, Kelemenova S, Celec P, Ficek A, Ostatnikova D:
Polymorphisms in genes involved in testosterone metabolism in Slovak
autistic boys. Endocrinologist 2010, 20:245–249.
32. Croonenberghs J, Van Grieken S, Wauters A, Van West D, Brouw L, Maes M,
Deboutte D: Serum testosterone concentration in male autistic
youngsters. Neuro Endocrinol Lett 2010, 31:483–488.
33. Strous RD, Golubchik P, Maayan R, Mozes T, Tuati-Werner D, Weizman A,
Spivak B: Lowered DHEA-S plasma levels in adult individuals with autistic
disorder. Eur Neuropsychopharmacol 2005, 15:305–309.
34. Tordjman S, Anderson GM, McBride PA, Hertzig ME, Snow ME, Hall LM, Ferrari P,
Cohen DJ: Plasma androgens in autism. J Autism Dev Disord 1995, 25:295–304.
35. Xu N, Kwon S, Abbott DH, Geller DH, Dumesic DA, Azziz R, Guo X, Goodarzi
MO: Epigenetic mechanism underlying the development of polycystic
ovary syndrome (PCOS)-like phenotypes in prenatally androgenized
rhesus monkeys. PLoS One 2011, 6:e27286.
36. Witham EA, Meadows JD, Shojaei S, Kauffman AS, Mellon PL: Prenatal
exposure to low levels of androgen accelerates female puberty onset
and reproductive senescence in mice. Endocrinology 2012, 153:4522–4532.
37. Terasawa E, Kurian JR, Keen KL, Shiel NA, Colman RJ, Capuano SV: Body
weight impact on puberty: effects of high-calorie diet on puberty onset
in female rhesus monkeys. Endocrinology 2012, 153:1696–1705.
38. Ibáñez L, Potau N, Virdis R, Zampolli M, Terzi C, Gussinyé M, Carrascosa A,
Vicens-Calvet E: Postpubertal outcome in girls diagnosed of premature
pubarche during childhood: increased frequency of functional ovarian
hyperandrogenism. J Clin Endocrinol Metab 1993, 76:1599–1603.
39. Maliqueo M, Sir-Petermann T, Pérez V, Echiburú B, de Guevara AL, Gálvez C,
Crisosto N, Azziz R: Adrenal function during childhood and puberty in
daughters of women with polycystic ovary syndrome. J Clin Endocrinol
Metab 2009, 94:3282–3288.
40. Sadrzadeh S, Klip WAJ, Broekmans FJ, Schats R, Willemsen WNP, Burger CW,
Van Leeuwen FE, Lambalk CB: Birth weight and age at menarche in
Pohl et al. Molecular Autism 2014, 5:27 Page 11 of 12
http://www.molecularautism.com/content/5/1/27patients with polycystic ovary syndrome or diminished ovarian reserve,
in a retrospective cohort. Hum Reprod 2003, 18:2225–2230.
41. Burney RO, Giudice LC: Pathogenesis and pathophysiology of
endometriosis. Fertil Steril 2012, 98:511–519.
42. Rubinow DR, Schmidt PJ: Gonadal steroid regulation of mood: the lessons
of premenstrual syndrome. Front Neuroendocrinol 2006, 27:210–216.
43. Young JK: Anorexia nervosa and estrogen: current status of the
hypothesis. Neurosci Biobehav Rev 2010, 34:1195–1200.
44. Reddy D: The role of neurosteroids in the pathophysiology and
treatment of catamenial epilepsy. Epilepsy Res 2009, 85:1–30.
45. Ingudomnukul E, Baron-Cohen S, Wheelwright S, Knickmeyer RC: Elevated
rates of testosterone-related disorders in women with autism spectrum
conditions. Horm Behav 2007, 51:597–604.
46. Baron-Cohen S, Wheelwright S, Skinner R, Martin J, Clubley E: The autism-
spectrum quotient (AQ): evidence from Asperger syndrome/high-functioning
autism, males and females, scientists and mathematicians. J Autism Dev Disord
2001, 31:5–17.
47. Wheelwright S, Auyeung B, Allison C, Baron-Cohen S: Defining the broader,
medium and narrow autism phenotype among parents using the Autism
Spectrum Quotient (AQ). Mol Autism 2010, 1:10.
48. Homburg R: Androgen circle of polycystic ovary syndrome. Hum Reprod
2009, 24:1548–1555.
49. Bohler H, Mokshagundam S, Winters SJ: Adipose tissue and reproduction
in women. Fertil Steril 2010, 94:795–825.
50. Nylund K, Apsparouhov T, Muthen B: Deciding on the number of classes
in latent class analysis and growth mixture modeling: a Monte Carlo
simulation study. Struct Equ Model A Multidiscip J 2007, 14:535–569.
51. Power RA, Kyaga S, Uher R, MacCabe JH, Långström N, Landen M, McGuffin
P, Lewis CM, Lichtenstein P, Svensson AC: Fecundity of patients with
schizophrenia, autism, bipolar disorder, depression, anorexia nervosa, or
substance abuse vs their unaffected siblings. JAMA Psychiatr 2013,
70:22–30.
52. Larsen F, Mouridsen SE: The outcome in children with childhood autism
and Asperger syndrome originally diagnosed as psychotic. A 30-year
follow-up study of subjects hospitalized as children. Eur Child Adolesc
Psychiatr 1997, 6:181–190.
53. Carmina E, Rosato F, Jannì A, Rizzo M, Longo RA: Extensive clinical
experience: relative prevalence of different androgen excess disorders
in 950 women referred because of clinical hyperandrogenism.
J Clin Endocrinol Metab 2006, 91:2–6.
54. Ong KK, Potau N, Petry CJ, Jones R, Ness AR, Honour JW, de Zegher F,
Ibáñez L, Dunger DB: Opposing influences of prenatal and postnatal
weight gain on adrenarche in normal boys and girls. J Clin Endocrinol
Metab 2004, 89:2647–2651.
55. Zukauskaite S, Seibokaite A, Lasas L, Lasiene D, Urbonaite B, Kiesylyte J:
Serum hormone levels and anthropometric characteristics in girls with
hyperandrogenism. Med (B Aires) 2005, 41:305–312.
56. Thankamony A, Ong KK, Ahmed ML, Ness AR, Holly JMP, Dunger DB: Higher
levels of IGF-I and adrenal androgens at age 8 years are associated with
earlier age at menarche in girls. J Clin Endocrinol Metab 2012,
97:E786–E790.
57. Fottner C, Engelhardt D, Weber MM: Regulation of steroidogenesis by
insulin-like growth factors (IGFs) in adult human adrenocortical cells:
IGF-I and, more potently, IGF-II preferentially enhance androgen
biosynthesis through interaction with the IGF-I receptor and IGF-binding
proteins. J Endocrinol 1998, 158:409–417.
58. Fahmy J, Kaminsky C: The radiological approach to precocious puberty. Br
J Radiol 2000, 73:560–567.
59. Knickmeyer RC, Wheelwright S, Hoekstra R, Baron-Cohen S: Age of menarche
in females with autism spectrum conditions. Dev Med Child Neurol 2006,
48:1007–1008.
60. Matchock RL: Low digit ratio (2D:4D) is associated with delayed
menarche. Am J Hum Biol 2008, 20:487–489.
61. Manning JT, Fink B: Is low digit ratio linked with late menarche? Evidence
from the BBC internet study. Am J Hum Biol 2011, 23:527–533.
62. De Zegher F, Ibáñez L: Prenatal growth restraint followed by catch-up of
weight: a hyperinsulinemic pathway to polycystic ovary syndrome.
Fertil Steril 2006, 86(Suppl 1):S4–S5.
63. Solorzano CMB, Mccartney CR, Blank SK, Karen L, Marshall JC:
Hyperandrogenemia in adolescent girls: origins of abnormal GnRH
secretion. Br J Obstet Gynaecol 2011, 117:143–149.64. Blank SK, McCartney CR, Marshall JC: The origins and sequelae of
abnormal neuroendocrine function in polycystic ovary syndrome.
Hum Reprod Update 2006, 12:351–361.
65. Sullivan SD, Moenter SM: GABAergic integration of progesterone and
androgen feedback to gonadotropin-releasing hormone neurons.
Biol Reprod 2005, 72:33–41.
66. Pielecka J, Quaynor SD, Moenter SM: Androgens increase gonadotropin-
releasing hormone neuron firing activity in females and interfere with
progesterone negative feedback. Endocrinology 2006, 147:1474–1479.
67. Sullivan SD, Moenter SM: Prenatal androgens alter GABAergic drive to
gonadotropin-releasing hormone neurons: implications for a common
fertility disorder. Proc Natl Acad Sci U S A 2004, 101:7129–7134.
68. Roland AV, Moenter SM: Glucosensing by GnRH neurons: inhibition by
androgens and involvement of AMP-activated protein kinase.
Mol Endocrinol 2011, 25:847–858.
69. Herzog AG, Harden CL, Liporace J, Pennell P, Schomer DL, Sperling M,
Fowler K, Nikolov B, Shuman S, Newman M: Frequency of catamenial
seizure exacerbation in women with localization-related epilepsy.
Ann Neurol 2004, 56:431–434.
70. Guille C, Spencer S, Cavus I, Epperson CN: The role of sex steroids in
catamenial epilepsy and premenstrual dysphoric disorder: implications
for diagnosis and treatment. Epilepsy Behav 2008, 13:12–24.
71. El-Khayat HA, Abd El-Basset FZ, Tomoum HY, Tohamy SM, Zaky AA,
Mohamed MS, Hakky SM, El Barbary NS, Nassef NM: Physical growth and
endocrinal disorders during pubertal maturation in girls with epilepsy.
Epilepsia 2004, 45:1106–1115.
72. Herzog AG, Coleman AE, Jacobs AR, Klein P, Friedman MN, Drislane FW,
Ransil BJ, Schomer DL: Interictal EEG discharges, reproductive hormones,
and menstrual disorders in epilepsy. Ann Neurol 2003, 54:625–637.
73. Tuchman R, Rapin I: Epilepsy in autism. Lancet Neurol 2002, 1:352–358.
74. Amiet C, Gourfinkel-An I, Bouzamondo A, Tordjman S, Baulac M, Lechat P,
Mottron L, Cohen D: Epilepsy in autism is associated with intellectual
disability and gender: evidence from a meta-analysis. Biol Psychiatr 2008,
64:577–582.
75. Han S, Tai C, Westenbroek RE, Yu FH, Cheah CS, Potter GB, Rubenstein JL,
Scheuer T, de la Iglesia HO, Catterall WA: Autistic-like behaviour in Scn1a
+/- mice and rescue by enhanced GABA-mediated neurotransmission.
Nature 2012, 489:385–390.
76. Belelli D, Bolger M, Gee K: Anticonvulsant profile of the progesterone
metabolite 5α-pregnan-3α-ol-20-one. Eur J Pharmacol 1989, 166:325–329.
77. Fadalti M, Petraglia F, Luisi S, Bernardi F, Casarosa E, Ferrari E, Luisi M,
Saggese G, Genazzani AR, Bernasconi S: Changes of serum
allopregnanolone levels in the first 2 years of life and during pubertal
development. Pediatr Res 1999, 46:323–327.
78. Genazzani AR, Petraglia F, Bernardi F, Casarosa E, Salvestroni C, Tonetti A,
Nappi RE, Luisi S, Palumbo M, Purdy RH, Luisi M: Circulating levels of
allopregnanolone in humans: gender, age, and endocrine influences.
J Clin Endocrinol Metab 1998, 83:2099–2103.
79. Genazzani AD, Chierchia E, Rattighieri E, Santagni S, Casarosa E, Luisi M,
Genazzani AR: Metformin administration restores allopregnanolone
response to adrenocorticotropic hormone (ACTH) stimulation in
overweight hyperinsulinemic patients with PCOS. Gynecol Endocrinol
2010, 26:684–689.
80. McCarthy MM, Auger AP, Perrot-Sinal TS: Getting excited about GABA and
sex differences in the brain. Trends Neurosci 2002, 25:307–312.
81. Cunningham J, Yonkers KA, O’Brien S, Eriksson E: Update on research and
treatment of premenstrual dysphoric disorder. Harv Rev Psychiatr 2009,
17:120–137.
82. Rastam M: Eating disturbances in autism spectrum disorders with focus
on adolescent and adult years. Clin Neuropsychiatr 2008, 5:31–42.
83. Hambrook D, Tchanturia K, Schmidt U, Russell T, Treasure J: Empathy,
systemizing, and autistic traits in anorexia nervosa: a pilot study.
Br J Clin Psychol 2008, 47:335–339.
84. Tchanturia K, Smith E, Weineck F, Fidanboylu E, Kern N, Treasure J, Baron
Cohen S: Exploring autistic traits in anorexia: a clinical study. Mol Autism
2013, 4:44.
85. Oldershaw A, Treasure J, Hambrook D, Tchanturia K, Schmidt U: Is anorexia
nervosa a version of autism spectrum disorders? Eur Eat Disord Rev 2011,
19:462–474.
86. Nilsson EW, Gillberg C, Råstam M: Familial factors in anorexia nervosa: a
community-based study. Compr Psychiatr 1998, 39:392–399.
Pohl et al. Molecular Autism 2014, 5:27 Page 12 of 12
http://www.molecularautism.com/content/5/1/2787. Hines M: Prenatal endocrine influences on sexual orientation and on
sexually differentiated childhood behavior. Front Neuroendocrinol 2011,
32:170–182.
88. Gargus JJ: Genetic calcium signaling abnormalities in the central nervous
system: seizures, migraine, and autism. Ann N Y Acad Sci 2009,
1151:133–156.
doi:10.1186/2040-2392-5-27
Cite this article as: Pohl et al.: Uncovering steroidopathy in women with
autism: a latent class analysis. Molecular Autism 2014 5:27.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
